Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open Access
- 1 May 2010
- journal article
- practice guideline
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_5), v172-v174
- https://doi.org/10.1093/annonc/mdq203
Abstract
Diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma series. The crude incidence in the European Union is 3–4/100 000/year. The incidence increases with age from 0.3/100 000/year (35–39 years) to 26.6/100 000/year (80–84 years).Keywords
This publication has 25 references indexed in Scilit:
- Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter studyHaematologica, 2009
- CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)Blood, 2009
- Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)Leukemia, 2007
- CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d’Etude des Lymphomes de l’AdulteJournal of Clinical Oncology, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- On the Road to New Drugs in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2007
- Is there a place for routine imaging for patients in complete remission from aggressive lymphoma?Annals of Oncology, 2006
- Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL studyAnnals of Oncology, 2006
- Changing trends in the incidence of non-Hodgkin's lymphoma in EuropeAnnals of Oncology, 1997
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995